ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK plus non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)

被引：2
|
作者：
Solomon, B. J. [1 ]
Wu, Y-L. [2 ]
Dziadziuszko, R. [3 ,4 ]
Barlesi, F. [5 ,6 ]
Nishio, M. [7 ]
Ahn, J. S. [8 ]
Horinouchi, H. [9 ]
Hochmair, M. J. [10 ]
de Marinis, F. [11 ]
Migliorino, M. R. [12 ]
Kurochkin, A. [13 ]
Harputluoglu, H. [14 ]
Planchard, D. [5 ,6 ]
Korphaisarn, K. [15 ]
Han, J-Y. [16 ]
Lohmann, T. [17 ]
Gavaldon, A. Cardona [18 ]
Archer, V. R. [19 ]
Nowicka, M. [20 ]
Noe, J. [21 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Acad Med Sci, Oncol Dept,Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[3] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
[4] Med Univ Gdansk, Early Phase Clin Trials Ctr, Gdansk, Poland
[5] Univ Paris Saclay, Dept Med Oncol, Villejuif, France
[6] Gustave Roussy, Villejuif, France
[7] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Thorac Med Oncol, Tokyo, Japan
[8] Samsung Med Ctr, Dept Hematol & Oncol, Seoul, South Korea
[9] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[10] Karl Landsteiner Inst Lung Res & Pulm Oncol, Klin Floridsdorf, Dept Resp & Crit Care Med, Vienna, Austria
[11] European Inst Oncol IRCCS, Thorac Oncol Div, Milan, Italy
[12] San Camillo Forlanini Hosp, Pneumooncol Unit, Rome, Italy
[13] RCI Sumy Reg Clin Oncol Dispensary, Oncothorac Surg Dept, Sumy Region, Kharkiv Governo, Ukraine
[14] Inonu Univ, Dept Med Oncol, Med Fac, Turgut Ozal Med Ctr, Malatya, Turkiye
[15] Mahidol Univ, Dept Med, Fac Med, Siriraj Hosp, Bangkok, Thailand
[16] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea
[17] F Hoffmann La Roche Ltd, PD Oncol, Basel, Switzerland
[18] F Hoffmann La Roche Ltd, Data & Stat Sci, Basel, Switzerland
[19] Roche Prod Ltd, PDC, Welwyn Garden City, Herts, England
[20] F Hoffmann La Roche Ltd, Computat Sci, Basel, Switzerland
[21] F Hoffmann La Roche Ltd, Translat Med, Basel, Switzerland
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1206MO
引用
收藏
页码：S775 / S775
页数：1
相关论文
共 50 条
  • [41] Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC)
    Solomon, B. J.
    Martini, J-F.
    Bearz, A.
    Tan, E. H.
    Soo, R.
    Besse, B.
    Bauer, T. M.
    Shepard, D.
    Toffalorio, F.
    Abbattista, A.
    Felip, E.
    Shaw, A. T.
    Viteri, S.
    Camidge, D. R.
    Seto, T.
    Ou, S-H. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S955 - S955
  • [42] Alectinib in resected ALK-positive non-small-cell lung cancer
    Gourmet, Anais
    Ferrari, Victoria
    BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906
  • [43] Comparison of cardiovascular effects of crizotinib and chemotherapy in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Wilner, K.
    Usari, T.
    Polli, A.
    Kim, E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S133 - S133
  • [44] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Dziadziuszko, Rafal
    Ahn, Jin Seok
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, M. Rita
    Bondarenko, Igor
    Lu, Shun
    Wang, Qun
    Ochi Lohmann, Tania
    Xu, Tingting
    Cardona, Andres
    Ruf, Thorsten
    Noe, Johannes
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
  • [45] Neo-adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
    Santo, A.
    Genestreti, G.
    Sava, T.
    Manno, P.
    Terzi, A.
    Molino, A. M.
    Cetto, G. L.
    ANNALS OF ONCOLOGY, 2006, 17 : V55 - V61
  • [46] Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC)
    Zaric, Bojan
    Stojsic, Vladimir
    Tepavac, Aleksandar
    Sarcev, Tatjana
    Zarogoulidis, Paul
    Darwiche, Kaid
    Tsakiridis, Kosmas
    Karapantzos, Ilias
    Kesisis, Georgios
    Kougioumtzi, Ioanna
    Katsikogiannis, Nikolaos
    Machairiotis, Nikolaos
    Stylianaki, Aikaterini
    Foroulis, Christophoros N.
    Zarogoulidis, Konstantinos
    Perin, Branislav
    JOURNAL OF THORACIC DISEASE, 2013, 5 : S371 - S377
  • [47] CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)
    Reckamp, K. L.
    Wakelee, H. A.
    Patel, S.
    Blumenschein, G.
    Neal, J. W.
    Gitlitz, B.
    Waqar, S. N.
    Tan, F.
    Harrow, K.
    Horn, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Ceritinib plus nivolumab (NIVO) in patients (pts) with anaplastic lymphoma kinase positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Felip, Enriqueta
    De Braud, Filippo G.
    Maur, Michela
    Loong, Herbert H. F.
    Shaw, Alice Tsang
    Vansteenkiste, Johan F.
    John, Tom
    Liu, Geoffrey
    Lolkema, Martijn P.
    Scott, Jeffrey W.
    Yu, Richard
    Selvaggi, Giovanni
    Mishra, Kaushal
    Lau, Yi-Yang Yvonne
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Symptoms of Bone and Liver Metastases in Patients with ALK plus Non-Small Cell Lung Cancer (NSCLC)
    Guerin, Annie
    Sasane, Medha
    Nitulescu, Roy
    Zhang, Jie
    Culver, Kenneth W.
    Wu, Eric Q.
    Macalalad, Alexander R.
    Dalai, Anand
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
  • [50] Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Pae, Elizabeth
    Babiker, Hani M.
    Garland, Linda L.
    Henglefelt, Alyssa
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345